The role of health economics and outcomes research in health care reform in China

PharmacoEconomics

Volumn 32, Issue 3, 2014, Pages 231-234

  Liang, Wannian ^a   Xie, Jipan ^b   Fu, Hongpeng ^c   Wu, Eric Q ^b  

^a Pharmacopoeia Commission of the People's Republic of China   (China)

^b ANALYSIS GROUP   (United States)

^c China National Development Research Center   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACHIEVEMENT; ARTICLE; CHINA; COST UTILITY ANALYSIS; EVIDENCE BASED PRACTICE; HEALTH CARE DISPARITY; HEALTH CARE POLICY; HEALTH ECONOMICS; HEALTH INSURANCE; HUMAN; MEDICAL DECISION MAKING; OUTCOMES RESEARCH; PRIORITY JOURNAL; DECISION MAKING; ECONOMICS; GOVERNMENT REGULATION; HEALTH SERVICES RESEARCH; LEGISLATION AND JURISPRUDENCE; OUTCOME ASSESSMENT;

CHINA; DECISION MAKING; EVIDENCE-BASED PRACTICE; GOVERNMENT REGULATION; HEALTH CARE REFORM; HEALTH SERVICES RESEARCH; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 84896313537     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-014-0141-2     Document Type: Article

References (33)

1. The Office of the Leading Group for Deepening the Reform of the Medical and Health Care System of the State Council. Q&A on deepening the medical and health care system reform [in Chinese]. Beijing: National Development and Reform Commission; 2009.
2. Ministry of Health. China public health statistical yearbook 2012 [in Chinese]. http://www.nhfpc.gov.cn/htmlfiles/zwgkzt/ptjnj/year2012/index2012. html. Accessed 25 Oct 2013.
3. Chen Z. Basic medical security systems cover 95% of the total population [in Chinese]. 2012 National Health Conference. 5 Jan 2012. http://money.163.com/ 12/0106/08/7N2Q8AN700253B0H.html. Accessed 25 Oct 2013.
4. Yang Q. 832 million people participate in NRCMS in China, participation rate exceeded 97%. The Ministry of Health press conference [in Chinese]. 27 Feb 2012. http://finance.chinanews. com/jk/2012/02-27/3700114.shtml. Accessed 25 Oct 2013.
5. Chen Z, Mao Z. Ending the subsidization of medical services with profits from the sales of medicines and deepening the reform of public hospitals. 8 Oct 2012. http://english.qstheory.cn/society/201210/t20121009-185287.htm. Accessed 13 Nov 2013.
6. General Office of the State Council. Notice of the General Office of the State Council on issuing the work arrangements for the reform of the medical and health care system in five key aspects [in Chinese]. Beijing: General Office of the State Council; 2010. http://www.gov.cn/zwgk/2010-04/19/content-1586732.htm. Accessed 25 Oct 2013.
7. People's Daily Online. China issues new essential drug list. 16 Mar 2013. http://english.peopledaily.com.cn/90882/8170200.html. Accessed 13 Nov 2013.
8. National Health Development Research Center. Green book on China health development: research on healthcare reforms [in Chinese]. Beijing: People's Medical Publishing House; 2013.
9. Manning WG, Newhouse JP, Duan N, et al. Health insurance and the demand for medical care: evidence from a randomized experiment. Am Econ Rev. 1987;77(3):251-77.
10. Casalino LP, Nicholson S, Gans DN, et al. What does it cost physician practices to interact with health insurance plans? Health Aff (Millwood). 2009;28(4):w533-43.
11. Cutler DM, Sahni NR. If slow rate of health care spending growth persists, projections may be off by $770 billion. Health Aff (Millwood). 2013;32(5):841-50.
12. Morgan SG, McMahon M, Mitton C, et al. Centralized drug review processes in Australia, Canada, New Zealand, and the United Kingdom. Health Aff (Millwood). 2006;25(2):337-47. (Pubitemid 43529541)
13. Liu GG, Eggleston K, Hu T. Emerging health economics and outcomes research in the Asia-Pacific region. Value Health. 2008;11(Suppl 1):S1-2. (Pubitemid 351490452)
14. Liu G, Tang Y, Liu L. The urban employee medical insurance policy analysis: medical savings account and medical expenditures. Finance Econ. 2009;1(250):45-52.
15. Langley PC, Mu R, Wu M, et al. The impact of rheumatoid arthritis on the burden of disease in urban China. J Med Econ. 2011;14(6):709-19.
16. Wang Y, Xu K, Hu H, et al. Prevalence, risk factors, and impact on health related quality of life of overactive bladder in China. Neurourol Urodyn. 2011;30(8):1448-55.
17. Wang R, Wu M, Ma X, et al. Body mass index and health-related quality of life in adults: a population based study in five cities in China. Eur J Public Health. 2012;22(4):497-502.
18. Jing S, Yin A, Shi L, Liu J. Whether New Cooperative Medical Schemes reduce the economic burden of chronic disease in rural China. PLoS One. 2013;8(1):e53062.
19. Babiarz KS, Miller G, Yi H, et al. New evidence on the impact of China's New Rural Cooperative Medical Scheme and its implications for rural primary healthcare: multivariate difference-indifference analysis. BMJ. 2010;341:c5617.
20. Wang S, Peng L, Li J, et al. A trial-based cost-effectiveness analysis of erlotinib alone versus platinum-based doublet chemotherapy as first-line therapy for Eastern Asian nonsquamous non-small-cell lung cancer. PLoS One. 2013;8(3):e55917.
21. Wu B, Ye M, Chen H, Shen JF. Costs of trastuzumab in combination with chemotherapy for HER2-positive advanced gastric or gastroesophageal junction cancer: an economic evaluation in the Chinese context. Clin Ther. 2012;34(2):468-79.
22. Peking University, China Center for Health Economics Research. China guidelines for pharmacoeconomic evaluations, 9 Apr 2011. http://www.ispor.org/ peguidelines/countrydet.asp?c=28&t=4. Accessed 25 Oct 2013.
23. Wu EQ, Xie J, Wu C, Du EX, Li N, Tan R, et al. Treatment, monitoring, and economic outcomes of venous thromboembolism among hospitalized patients in China. PharmacoEconomics. 2014. doi:10.1007/s40273-014-0131-4
24. Wang Y, Wang Y, Qain Y, Zhang J, Tang X, Sun J, Zhu D. Association of body mass index with cause specific deaths in Chinese elderly hypertensive patients: Minhang community study. PLoS One. 2013;8(8):e71223.
25. Xue Q, Xiong X, Feng Y, Yao L, Chen S, Xiang L. Socioeconomic factors influencing anti psychotic prescription for schizophrenia inpatients in China: a cross-sectional study. Int Clin Psychopharmacol. Epub 2013 Dec 7.
26. Wu EQ, Wu J, Yang HY, Zheng Y, Xie K, Yu R, Xie J. Economic burden of hepatocellular carcinoma in China. Presented at the ISPOR 17th Annual International Meeting poster session, Washington, DC, 2012 Jun 2-6.
27. Xu J, Liu G, Deng G, Li L, Xiong X, Basu K. A comparison of outpatient healthcare expenditures between public and private medical institutions in urban China: an instrumental variable approach. Health Econ. Epub 2013 Dec 11.
28. Chen G, Liu GG, Xu F. The impact of the urban resident basic medical insurance on health services utilisation in China. PharmacoEconomics. 2014. doi:10.1007/s40273-013-0097-7
29. Chen M, Wang L, Chen W, Zhang L, Jiang H, Mao W. Does economic incentive matter for rational use of medicine? China's experience from the essential medicines program. Pharmaco-Economics. 2014. doi:10.1007/s40273-013-0068-z
30. Wu J, Xu J, Liu GG, Wu J. Pharmaceutical pricing: an empirical study of market competition in Chinese hospitals. Pharmaco-Economics. 2014. doi:10.1007/s40273-013-0099-5
31. Shi L, Yang HY, Cheng G, Meng Q. Time trends and determinants of pharmaceutical expenditure in China (1990-2009). PharmacoEconomics. 2014. doi:10.1007/s40273-013-0072-3
32. Yuan S, Liu Y, Li N, Zhang Y, Zhang Z, Tao J, et al. Impacts of health insurance benefit design on percutaneous coronary intervention use and inpatient costs among patients with acute myocardial infarction in Shanghai, China. PharmacoEconomics. 2014. doi:10.1007/s40273-013-0079-9
33. Chongqing T, Liubao P, Xiaohui Z, Jianhe L, Xiaomin W, Gannong C, et al. Cost-utility analysis of the newly recommended adjuvant chemotherapy for resectable gastric cancer patients in the 2011 Chinese National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology: gastric cancer. PharmacoEconomics. 2014. doi:10.1007/s40273-013-0065-2